University of Wisconsin-Madison: Antivirals, Some Antibodies, Work Well Against BA.2 Omicron Variant of COVID-19 Virus
March 11, 2022
March 11, 2022
MADISON, Wisconsin, March 11 (TNSJou) -- The University of Wisconsin Madison campus issued the following news:
By Eric Hamilton
The antiviral therapies remdesivir, molnupiravir, and the active ingredient in Pfizer's Paxlovid pill (nirmatrelvir), remain effective in laboratory tests against the BA.2 variant of SARS-CoV-2, the virus that causes COVID-19.
The BA.2 variant also remains susceptible to at least some of the monoclonal antibodies used to treat . . .
By Eric Hamilton
The antiviral therapies remdesivir, molnupiravir, and the active ingredient in Pfizer's Paxlovid pill (nirmatrelvir), remain effective in laboratory tests against the BA.2 variant of SARS-CoV-2, the virus that causes COVID-19.
The BA.2 variant also remains susceptible to at least some of the monoclonal antibodies used to treat . . .